Ipsen gets FDA approval of Dysport for treatment of Upper Limb Spasticity in children, excluding cerebral palsy

Ipsen got approval for Dysport, the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity, as the pivotal Phase 3 study showed Dysport improved spasticity symptoms in children aged two to 17 experiencing upper limb spasticity, as measured by the primary efficacy endpoint of Modified Ashworth Scale at elbow or wrist flexors at Week 6.

Read more